阿尔及利亚24h新闻网1月8日报道，阿尔及利亚医药工业部发布声明称，该部与卫生部代表同阿曼投资 机构代表以视频会议方式举行会谈，就两国企业在制药领域的联合投资机会进行研究和讨论。会议旨在 落实双边合作框架，推动将共同政治意愿转化为具体项目和务实合作。双方一致同意加强协调配合，通 过人员互访并制定明确时间表，推进既定路线图落地实施。声明指出，此次会议也是落实医药工业部长 古维德里去年12月访问阿曼成果的重要举措，重点围绕发展制药产业、技术与经验交流、科研合作与技 术转移，以及便利阿尔及利亚医药产品进入阿曼及周边市场等领域深化合作。 ...

Core Insights - The 2025 China-Indonesia Pharmaceutical Packaging Development Forum was held in Jakarta, aiming to deepen practical cooperation between China and Indonesia in the pharmaceutical packaging and excipient sectors [1][4] - The forum gathered around 80 representatives from Indonesia's Ministry of Health, Food and Drug Administration, pharmaceutical companies, and Chinese pharmaceutical packaging and excipient enterprises [1][2] Group 1 - Indonesia, as the largest economy in Southeast Asia, has a rapidly growing pharmaceutical market but relies heavily on imports for raw materials and packaging [2] - The forum focused on Indonesia's pharmaceutical market status, entry policies, industry demands, and China's drug regulatory system, facilitating accurate cooperation direction [2][3] - The Chinese Pharmaceutical Packaging Association's Executive President, Cai Hong, expressed hopes for establishing a long-term and stable cooperative relationship through this forum [2] Group 2 - During the forum, expert Ma Yunan introduced China's drug registration and regulatory system, while representatives from Indonesia shared insights on the country's pharmaceutical industry development and policies [2][3] - The Indonesian Ministry of Health representative, Dita Novianti, noted the rapid growth of Indonesia's pharmaceutical manufacturing industry but highlighted limited space for innovative products in the market [3] - The forum featured an exhibition area where seven Chinese pharmaceutical packaging companies showcased their core products, attracting significant attention from Indonesian industry officials and representatives [2][3] Group 3 - On November 19, the Chinese delegation visited several Indonesian pharmaceutical companies and hospitals to understand production processes, quality control standards, and actual packaging application needs [3] - The forum established an important platform for information sharing, technical exchange, and commercial cooperation in the pharmaceutical packaging sector [3] - This initiative aims to promote high-quality Chinese pharmaceutical packaging products and technologies into the Indonesian market, addressing the growing healthcare needs of nearly 300 million local residents [3]

Core Viewpoint - The acquisition of 11.04% equity in Nanjing Pharmaceutical by the buyer, Guangzhou Pharmaceutical Phase II Fund, for RMB 748.8 million, aims to strengthen strategic cooperation between the companies and enhance their competitive advantage in the pharmaceutical distribution industry [1][4]. Group 1: Acquisition Details - The buyer will acquire 11.04% equity in Nanjing Pharmaceutical, with a transaction value of RMB 748.8 million [1]. - Following the acquisition, the buyer will hold 11.04% equity in the target company [1]. Group 2: Strategic Cooperation - A strategic investment agreement has been established to enhance collaboration in capital operations, including potential joint ventures and strategic investments [1]. - The companies will work together to optimize supply chain resources and logistics, focusing on market access and sales for their proprietary industrial products [2]. - Both companies will support the transformation and modernization of traditional Chinese medicine, establishing a comprehensive traceability system for Chinese medicinal materials [3]. Group 3: Company Background - Nanjing Pharmaceutical is a well-known regional enterprise in the pharmaceutical distribution industry, with a market network covering Jiangsu, Anhui, Hubei, Fujian, and Kunming [3]. - The controlling shareholder of Nanjing Pharmaceutical is Nanjing New Industry Group, which holds 44.17% of its shares [3].

Core Viewpoint - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. announced the acquisition of 11.04% shares of Nanjing Pharmaceutical Co., Ltd. from Alliance Healthcare Asia Pacific Limited for 749 million RMB, making Baiyunshan the second-largest shareholder of Nanjing Pharmaceutical [1][2] Group 1 - The acquisition price is based on the average closing price of Nanjing Pharmaceutical's shares over the previous 60 trading days, set at 5.18 RMB per share [1] - The strategic investment agreement signed includes collaboration in capital cooperation, distribution channels for proprietary industrial products, and cooperation in traditional Chinese medicine [1][2] Group 2 - This transaction is expected to enhance Baiyunshan's business cooperation with Nanjing Pharmaceutical, optimize regional industrial layout, and strengthen competitive advantages in the pharmaceutical distribution business [2] - The Baiyunshan-funded Guangzhou Traditional Chinese Medicine Phase II Fund was established with a total investment of 1.499 billion RMB, focusing on investments in the biopharmaceutical and health sectors [2]